Education
About Us
Working with TipRanks
Follow Us
Immunovant (IMVT)
NASDAQ:IMVT
Earnings Data
Report Date
Jun 03, 2026Before Open (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
-0.61Last Year’s EPS
-0.64Same Quarter Last Year
Strong Buy
Based on 10 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed substantial positive momentum driven by exceptionally strong Phase II brepocitinib data in cutaneous sarcoidosis, multiple fully enrolled studies and a solid cash position to fund upcoming registrational activity. Key operational highlights include the brepo NDA in dermatomyositis, fully enrolled 1402 D2T RA and mosliciguat PH‑ILD studies, and constructive legal progress ahead of a March jury trial. Offsetting risks are the small size and baseline imbalances of the CS Phase II study (creating uncertainty aboutPhase III translation), ongoing litigation and evidentiary motions, continued high operating spend and typical regulatory/development timing uncertainties. Overall, the positives (clinical wins, pipeline momentum, enrollment success and cash runway) materially outweigh the programmatic and legal uncertainties identified on the call.Company Guidance
Strong Phase II brepocitinib efficacy in cutaneous sarcoidosis
Placebo‑adjusted mean CSAMI improvement ~21.6 points (study was not powered for efficacy); 100% of patients on brepocitinib 45 mg achieved ≥10‑point CSAMI improvement; 62% of 45 mg patients achieved CSAMI <5 (functional remission); statistically significant separation vs placebo as early as Week 4 and sustained through Week 16.
Favorable safety and large existing brepocitinib database
No serious adverse events in the Phase II CS study; all adverse events were mild or moderate and safety was consistent with the compound's broader database of >1,500 patients, supporting a potentially favorable benefit‑risk profile.
Pipeline and registrational momentum
NDA for brepocitinib in dermatomyositis submitted; NIU Phase III pivotal readout expected in H2 2026; company to initiate a Phase III in cutaneous sarcoidosis this year; management cites 9+ pivotal study readouts across the portfolio in the coming years.
Enrollment achievements and upcoming catalysts
IMVT‑1402 (D2T RA) Phase IIb fully enrolled with 170 patients (up from an anticipated 120, a +41.7% increase in enrollment vs plan); mosliciguat PH‑ILD Phase II fully enrolled; top‑line data for mosliciguat and D2T RA expected in the second half of 2026.
Strong cash position to fund development
Consolidated cash balance of $4.5 billion provides runway for ongoing and planned registrational programs; company retains share buyback authorization.
Immunovant FcRn franchise progress
IMVT‑1402 highlighted as a potential best‑in‑class FcRn program with convenient subcutaneous administration; pivotal data in Graves' disease expected in 2027, supporting future commercial opportunity.
Favorable pretrial legal development
Received a favorable summary judgment decision on Section 1498 ahead of the Moderna jury trial (trial scheduled to begin March 9), which management views as constructive to their litigation posture.
Consistent patient‑reported outcome improvements
Multiple PROs (Skindex‑16, KSQ skin domain, Patient Global Impression of Change) showed substantial improvement for brepocitinib arms, with 100% of 45 mg patients reporting improvement on PGIC—supporting physician‑reported findings.
IMVT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IMVT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 06, 2026 | $24.06 | $27.05 | +12.43% |
Nov 10, 2025 | $23.35 | $23.37 | +0.09% |
Aug 11, 2025 | $15.46 | $14.76 | -4.53% |
May 29, 2025 | $14.10 | $14.89 | +5.60% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Immunovant (IMVT) report earnings?
Immunovant (IMVT) is schdueled to report earning on Jun 03, 2026, Before Open (Confirmed).
What is Immunovant (IMVT) earnings time?
Immunovant (IMVT) earnings time is at Jun 03, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IMVT EPS forecast?
IMVT EPS forecast for the fiscal quarter 2026 (Q4) is -0.61.